From July 2008 through December 2008, we continued to monitor antiviral susceptibility of all infl uenza A (H1N1) viruses in our laboratory, using previously described methods (1) . Resistance to oseltamivir increased from 16.9% in July to 97.8% in December (Table) Patient 2, a 62-year-old woman, experienced a high fever, cough, and nasal congestion during a prolonged hospitalization for bowel resection after intestinal ischemia. Pandemic (H1N1) 2009 was confi rmed by PCR and viral culture. Oseltamivir was administered 5 days after the onset of symptoms, and the symptoms resolved within the following 5 days. The patient had a new episode of fever, productive cough, and bronchial obstruction 2 weeks later while still hospitalized. Culture results were positive for infl uenza, and PCR results were positive for pandemic (H1N1) 2009. The patient was again treated with oseltamivir, and PCR results were negative for infl uenza after 48 hours of antiviral treatment.
Patient 3, a previously healthy 38-year-old man, underwent mitral and aortic valve replacement while hospitalized for acute mitral and aortic endocarditis due to Staphylococcus aureus. Eleven days after surgery, he had a sore throat, nasal congestion, cough, and low-grade fever. PCR test results were positive for pandemic (H1N1) 2009. The patient received oseltamivir, and respiratory symptoms resolved within 5 days. He was discharged from the hospital but was
